

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 12,268,664 B1
APPLICATION NO. : 18/782666
DATED : April 8, 2025
INVENTOR(S) : Steve Cartt et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


In the Specification

Please insert the following paragraph after Column 1, Line 17:

--JOINT RESEARCH AGREEMENT

The subject matter disclosed was developed and the claimed invention was made by or on behalf of the following parties to a joint research agreement: Particle Sciences, Inc. and Questcor Pharmaceuticals, Inc. (as predecessor-in-interest to Hale BioPharma Ventures, LLC).--

Signed and Sealed this
Tenth Day of February, 2026



John A. Squires
Director of the United States Patent and Trademark Office



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
18/782,666	07/24/2024	Steve CARTT	148570-014311	7831
185628	7590	02/10/2026	EXAMINER	
DLA Piper LLP (US)/Pittsburgh 1650 Market Street, Suite 5000 Philadelphia, PA 19103			COHEN, MICHAEL P	
			ART UNIT	PAPER NUMBER
			1612	
			NOTIFICATION DATE	DELIVERY MODE
			02/10/2026	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ip.pitt@us.dlapiper.com



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.
18/782,666	10-Feb-2026	12268664

DLA Piper LLP (US)/Pittsburgh
Philadelphia, PA 19103

ELECTRONIC CERTIFICATE OF CORRECTION NOTIFICATION

Your electronic certificate of correction is now available, and can be accessed via Patent Center at <https://patentcenter.uspto.gov>.

The electronic certificate of correction is the official certificate of correction under 35 U.S.C. 254 or 255. For more information, please visit <https://www.uspto.gov/electronicgrants>.

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**Page 1 of 1

PATENT NO. : 12,268,664

APPLICATION NO.: 18/782,666

ISSUE DATE : April 8, 2025

INVENTOR(S) : Steve CARTT, David MEDEIROS, Garry Thomas GWOZDZ, Andrew LOXLEY, Mark MITCHNICK, David F. HALE and Edward T. MAGGIO

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please insert the following paragraph immediately after paragraph [001]:

JOINT RESEARCH AGREEMENT

[002] The subject matter disclosed was developed and the claimed invention was made by or on behalf of the following parties to a joint research agreement: Particle Sciences, Inc. and Questcor Pharmaceuticals, Inc. (as predecessor-in-interest to Hale BioPharma Ventures, LLC).

MAILING ADDRESS OF SENDER (Please do not use Customer Number below):

DLA Piper LLP (US)
1650 Market Street, Suite 5000
Philadelphia, PA 19103-007300

A Federal agency may not conduct or sponsor, and a person is not required to respond to, nor shall a person be subject to a penalty for failure to comply with an information collection subject to the requirements of the Paperwork Reduction Act of 1995, unless the information collection has a currently valid OMB Control Number. The OMB Control Number for this information collection is 0651-0033. Public burden for this form is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the information collection. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden to the Chief Administrative Officer, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450 or email InformationCollection@uspto.gov. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. If filing this completed form by mail, send to: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

NEURELIS, INC., EX2078, page 4
PADAGIS US LLC v. NEURELIS, INC.
IPR2025-00466, U.S. PATENT 11,793,786

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of : Steve CARTT, et al.
Patent No. : 12,268,664 B1
Issued : April 8, 2025
Application No. : 18/782,666
Filed : July 24, 2024
Group Art Unit : 1612
Confirmation No. : 7831
Examiner : Michael P. Cohen
Title: ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS

TRANSMITTAL LETTER

CERTIFICATES OF CORRECTION BRANCH

Office of Data Management
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

Transmitted herewith for the above-identified patent please find:

1. Request for Certificate of Correction under 37 CFR §1.323 (Applicant's mistake) (2 pages); and
2. One (1) Sheet of PTO Form SB/44 Certificate of Correction (1 page).

The fees for this filing total \$172.00, which consist of \$172.00 for the Certificate of Correction fee as required by 37 CFR §1.323 and 37 CFR §1.20(a). The Certificate of Correction merely adds the names of the parties to a joint research agreement and, therefore, does not constitute new matter pursuant to MPEP § 2156. The Commissioner is hereby authorized to charge any other fees associated with the filing submitted herewith or credit any overpayments to Deposit Account No. 60-4406.

Respectfully submitted,

DLA PIPER LLP (US)

/Dennis J. Parad/

Dennis J. Parad
Reg. No. 60,280
Attorney for Applicant

DLA PIPER LLP (US)
1650 Market Street, Suite 5000
Philadelphia, PA 19103-7348
Telephone: (215) 656-3300
Date: December 15, 2025

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors:	Steve CARTT, et al.	Art Unit:	1612
Patent No.:	12,268,664 B1	Examiner:	Michael P. Cohen
Issued:	April 8, 2025	Conf. No.:	7831
Application No.:	18/782,666		
Filed:	July 24, 2024		
Title:	ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS		

CERTIFICATES OF CORRECTION BRANCH

Office of Data Management
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR §1.323

Sir:

Applicant hereby requests that a Certificate of Correction be issued for the above-identified patent in accordance with 37 C.F.R. §1.323 (Applicant's mistake).

Attached hereto is One (1) Sheet of PTO Form SB/44, identifying the errors by reference to column and line number of the issued patent.

The error sought to be corrected in this patent was made in good faith and without deceptive intent. The Certificate of Correction merely adds the names of the parties to a joint research agreement and, therefore, does not constitute new matter pursuant to MPEP § 2156. Accordingly, Applicant submits that the Request for Certificate of Correction does not raise issues of new matter, nor does it require reexamination.

In re Patent of: Steve CARTT, et al.

PATENT
Attorney Docket No.: 148570-014311

Patent No.: 12,268,664 B2
Issued: April 8, 2025
Application No.: 18/782,666
Filed: July 24, 2024
Page 2

In view of the above statements and the attachments, it is respectfully requested that a Certificate of Correction for U.S. Patent No. 12,268,664 B1 be issued.

If a telephone conference with Applicant's representative may be of assistance, Applicant's representative can be reached at the phone number and address below.

The fees for this filing total \$172.00, which consist of \$172.00 for the Certificate of Correction fee as required by 37 CFR §1.323 and 37 CFR §1.20(a). The Commissioner is hereby authorized to charge any other fees associated with the filing submitted herewith, or credit any overpayments to Deposit Account No. 60-4406.

Respectfully submitted,

DLA PIPER LLP (US)
/Dennis J. Parad/

Dennis J. Parad
Reg. No. 60,280
Attorney for Applicant

DLA PIPER LLP (US)
1650 Market Street, Suite 5000
Philadelphia, PA 19103-7348
Telephone: (215) 656-3300
Date: December 15, 2025



UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC PAYMENT RECEIPT

APPLICATION #
18/782,666

RECEIPT DATE / TIME
12/15/2025 02:52:08 PM Z ET

ATTORNEY DOCKET #
148570-014311

Title of Invention

ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS

Application Information

APPLICATION TYPE Utility - Nonprovisional Application
under 35 USC 111(a)

PATENT # 12268664

CONFIRMATION # 7831

FILED BY Charles Vrscak

PATENT CENTER # 73593451

AUTHORIZED BY DENNIS PARAD

CUSTOMER # 185628

FILING DATE 07/24/2024

CORRESPONDENCE ADDRESS -

FIRST NAMED INVENTOR Steve CARTT

Payment Information

PAYMENT METHOD
DA / 604406

PAYMENT TRANSACTION ID
E2025BEE54178111

PAYMENT AUTHORIZED BY
Charles Vrscak

PRE-AUTHORIZED ACCOUNT
604406

PRE-AUTHORIZED CATEGORY
37 CFR 1.16 (National application filing, search, and examination fees); 37 CFR 1.17 (Patent application and reexamination processing fees); 37 CFR 1.19 (Document supply fees); 37 CFR 1.20 (Post Issuance fees); 37 CFR 1.21 (Miscellaneous fees and charges)

FEE CODE	DESCRIPTION	ITEM PRICE(\$)	QUANTITY	ITEM TOTAL(\$)
1811	CERTIFICATE OF CORRECTION	172.00	1	172.00
TOTAL AMOUNT:				\$172.00

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for NEURELIS, INC. 18/782,666 (page 9)

PADAGIS US LLC v. NEURELIS, INC.
IPR2025-00466, U.S. PATENT 11,793,786

and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES
PATENT AND TRADEMARK OFFICEP.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov**ELECTRONIC ACKNOWLEDGEMENT RECEIPT**APPLICATION #
18/782,666RECEIPT DATE / TIME
12/15/2025 02:52:08 PM Z ETATTORNEY DOCKET #
148570-014311**Title of Invention**

ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS

Application InformationAPPLICATION TYPE Utility - Nonprovisional Application
under 35 USC 111(a)

PATENT # 12268664

CONFIRMATION # 7831

FILED BY Charles Vrscak

PATENT CENTER # 73593451

FILING DATE 07/24/2024

CUSTOMER # 185628

FIRST NAMED
INVENTOR Steve CARTTCORRESPONDENCE
ADDRESS -

AUTHORIZED BY DENNIS PARAD

Documents**TOTAL DOCUMENTS: 3**

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
Transmittal_ltr_Cert_of_Correction_15Dec2025.pdf	2	Transmittal Letter	102 KB
Req_Cert_of_Correction_15Dec2025.pdf	2	Request for Certificate of Correction	105 KB
Cert_of_Correction_15Dec2025.pdf	1	Request for Certificate of Correction	609 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
Transmittal_ltr_Cert_of_Correction_15Dec2025.pdf	8C55BDAB01C3C95A43D46E3E582325EDE63E97174608D14F19DA395368519ED934371A59EAA30B45CE8456817CACE5841E

NEURELIS, INC., EX2078, page 11
PADAGIS US LLC v. NEURELIS, INC.
IPR2025-00466, U.S. PATENT 11,793,786

D03092B61E5ECBFBEC486A7F6249BB

Req_Cert_of_Correction_15Dec2025.pdf

43D069C07D41E9A3BD513CFA9F0479044E546548038D0316E
5B54B9D25D2DC9CA297E15D5A02FF172B6E800C32935D87C
A2B10B933BA6EA194C7C0A4E2873D0F

Cert_of_Correction_15Dec2025.pdf

89AEF75ED11D59CFD8003468838625C891F384C232849E3DB
2E243FE979E152AD958F139335E0303705D1E9732945AABD7
E3931FC6A6561922A719A25E6AF29B

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.